Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC25B | P30305 | 11/20 | 1.00 |
| ▸ | CDC25A | P30304 | 8/20 | 1.00 |
| ▸ | MAP2K7 | O14733 | 6/20 | 1.00 |
| ▸ | S100A4 | P26447 | 8/20 | 0.75 |
| ▸ | MEN1 | O00255 | 4/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.54 |
| ▸ | APEX1 | P27695 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 4/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | RAB9A | P51151 | 3/20 | 0.52 |
| ▸ | BLM | P54132 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | APAF1 | O14727 | 3/20 | 0.52 |
| ▸ | TDP2 | O95551 | 3/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | PLA2G1B | P04054 | 2/20 | 0.52 |
| ▸ | THRB | P10828 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2599369 | 0.86 | S100A4 (1.00) | CDC25BCDC25AMAP2K7S100A4MEN1 | |
| SCHEMBL30996023 | 0.84 | CDC25B (0.72) | CDC25BCDC25AMAP2K7S100A4MEN1 | |
| SCHEMBL11884727 | 0.84 | CDC25B (0.72) | CDC25BCDC25AMAP2K7S100A4MEN1 | |
| SCHEMBL11573754 | 0.84 | CDC25B (0.72) | CDC25BCDC25AMAP2K7S100A4MEN1 | |
| SCHEMBL14232080 | 0.81 | CDC25A (0.67) | CDC25BCDC25AMAP2K7S100A4MEN1 | |
| Anthraquinone SCHEMBL9329779 | 0.76 | MEN1 (0.92) | CDC25BCDC25AMAP2K7S100A4MEN1 | |
| Anthraquinone SCHEMBL5958714 | 0.74 | CDC25B (0.86) | CDC25BCDC25AMAP2K7S100A4MEN1 | |
| 9,10-Phenanthrenequinone SCHEMBL28594289 | 0.74 | S100A4 (0.93) | CDC25BCDC25AMAP2K7S100A4MEN1 | |
| Bromide SCHEMBL28112335 | 0.74 | MEN1 (0.86) | CDC25BCDC25AMAP2K7S100A4MEN1 | |
| SCHEMBL10502004 | 0.73 | NPC1 (0.59) | CDC25BCDC25AMAP2K7S100A4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9040713-B2 | Methods of managing blood sugar levels and compositions related thereto | EMORY UNIVERSITY (US) | 2015-05-26 | — | — | US | disclosed |
| US-20130158082-A1 | METHODS OF MANAGING BLOOD SUGAR LEVELS AND COMPOSITIONS RELATED THERETO | EMORY UNIVERSITY (US) | 2013-06-20 | — | — | US | disclosed |
| WO-2012047628-A2 | METHODS OF MANAGING BLOOD SUGAR LEVELS AND COMPOSITIONS RELATED THERETO | EMORY UNIVERSITY (US) | 2012-04-12 | — | — | WO | disclosed |
| WO-2005042442-A2 | 2-METHYLTHIO-1,4-NAPHTHOQUINONE DERIVATIVES, METHODS FOR THE PRODUCTION THEREOF, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND USE THEREOF | Johannes Gutenberg-Universität Mainz (DE) | 2005-05-12 | — | — | WO | disclosed |
| EP-0146145-B1 | NAPHTHALENE ANTI-PSORIATIC AGENTS | SYNTEX (U.S.A.) INC. (US) | 1989-08-30 | — | — | EP | disclosed |
| US-4593120-A | Naphthalene-1,4-dicarboxylic acid group | SYNTEX (U.S.A.) INC. (US) | 1986-06-03 | — | — | US | disclosed |
| EP-0107512-B1 | 1,4-ACYLOXYNAPHTHALENE DERIVATIVES, TOPICAL COMPOSITIONS CONTAINING THEM, METHODS FOR THEIR PREPARATION, AND INTERMEDIATES THEREFOR | SYNTEX (U.S.A.) INC. (US) | 1986-02-26 | — | — | EP | disclosed |
| EP-0146145-A2 | Naphthalene anti-psoriatic agents | SYNTEX (U.S.A.) INC. (US) | 1985-06-26 | — | — | EP | disclosed |
| US-4466981-A | Naphthalene anti-psoriatic agents | SYNTEX (U.S.A.) INC. (US) | 1984-08-21 | — | — | US | disclosed |
| EP-0107512-A1 | 1,4-Acyloxynaphthalene derivatives, topical compositions containing them, methods for their preparation, and intermediates therefor | SYNTEX (U.S.A.) INC. (US) | 1984-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158082-A1 | METHODS OF MANAGING BLOOD SUGAR LEVELS AND COMPOSITIONS RELATED THERETO | SLC5A1, SLC2A1, SLC5A2 | CDC25B 4287/4885CDC25A 3454/4885MAP2K7 3485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.